DNA starts Herceptin studies in early-stage breast cancer

Genentech (DNA) said it is running four Phase III trials of its Herceptin trastuzumab anti- HER2 monoclonal antibody in combination with chemotherapy in more than 10,000 patients with early-stage brea...